Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | CNR1 | P21554 | 1/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.52 |
| ▸ | CNR2 | P34972 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | SFRP1 | Q8N474 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4619139 | 0.90 | ALDH1A1 (0.64) | ALDH1A1CNR1CYP19A1CNR2LMNA | |
| SCHEMBL4617469 | 0.89 | SFRP1 (0.65) | ALDH1A1SMN1; SMN2MAPTSFRP1 | |
| SCHEMBL4617440 | 0.89 | ALDH1A1 (0.58) | ALDH1A1CYP19A1CNR2LMNATSHR | |
| SCHEMBL4616070 | 0.86 | SFRP1 (0.66) | ALDH1A1CYP19A1LMNASMN1; SMN2MAPT | |
| SCHEMBL6103073 | 0.82 | SFRP1 (0.61) | ALDH1A1CNR1LMNASMN1; SMN2MAPT | |
| SCHEMBL4618307 | 0.80 | SFRP1 (0.64) | ALDH1A1CNR1SMN1; SMN2SFRP1 | |
| SCHEMBL6103295 | 0.80 | SFRP1 (0.75) | ALDH1A1LMNAHTTMAPTSFRP1 | |
| SCHEMBL4617536 | 0.80 | SFRP1 (0.67) | ALDH1A1SMN1; SMN2SFRP1 | |
| SCHEMBL4616896 | 0.79 | SFRP1 (0.52) | ALDH1A1LMNATSHRHTTSMN1; SMN2 | |
| SCHEMBL4618783 | 0.79 | SFRP1 (0.80) | ALDH1A1HTTSMN1; SMN2SFRP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | WYETH (US) | 2006-12-07 | — | — | US | claimed |
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | SFRP1, SOS1, FZD7 | ALDH1A1 1865/4885CNR1 2978/4885CYP19A1 1047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.